Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression

Wajs, Ewa; Aluisio, Leah; Holder, Richard; Daly, Ella; Lane, Rosanne; Lim, Pilar; E. George, Joyce; L. Morrison, Randall; Sanacora, Gerard; H. Young, Allan; Kasper, Siegfried; Hatim Sulaiman, Ahmad; Li, Cheng‐Ta; Paik, Jong‐Woo; K. Manji, Husseini; Hough, David; Grunfeld, Jennifer; Jin Jeon, Hong; T. Wilkinson, Samuel; C. Drevets, Wayne; Singh, Jaskaran

doi:10.4088/jcp.19m12891

Public

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression

Published in The Journal of Clinical Psychiatry • Apr 20, 2020

Authors:

Ewa Wajs

Leah Aluisio

Richard Holder

Abstract

OBJECTIVE: To evaluate long-term safety and efficacy of esketamine nasal spray plus a new oral antidepressant (OAD) in patients with treatment-resistant depression (TRD). METHODS: This phase 3, open-label, multicenter, long-term (up to 1 year) study was conducted between October 2015 and October 201...

Subject

Medicine

Nausea

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!